研究疾病:
|
COPD稳定期
|
研究疾病代码:
|
|
Target disease:
|
COPD stable period
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
1.主要目的:评价痰饮丸用于COPD稳定期(脾肾阳虚,痰饮阻肺证)对延缓AECOPD发作的疗效。
2.次要目的:
(1)评价痰饮丸用于COPD稳定期(脾肾阳虚,痰饮阻肺证)对症状的改善作用;
(2)评价痰饮丸用于COPD稳定期(脾肾阳虚,痰饮阻肺证)对AECOPD发作次数的改善作用;
(3)评价痰饮丸用于COPD稳定期(脾肾阳虚,痰饮阻肺证)对生活质量的改善作用;
(4)评价痰饮丸临床使用的安全性;
(5)探索痰饮丸治疗COPD稳定期(脾肾阳虚,痰饮阻肺证)“冬病夏治”理念临床应用的有效性。
|
Objectives of Study:
|
1.Main purpose: Evaluate the efficacy of Tanyin Pills in the stable phase of COPD (spleen and kidney yang deficiency, phlegm obstructing lung syndrome) on delaying the onset of AECOPD.
2.Secondary purpose:
(1) To evaluate the effect of Tanyin Pills on the symptoms of stable COPD (spleen and kidney yang deficiency, phlegm obstructing the lung syndrome);
(2) To evaluate the effect of Tanyin Pills in the stable period of COPD (spleen and kidney yang deficiency, phlegm obstructing the lung syndrome) on improving the number of AECOPD attacks;
(3) To evaluate the effect of Tanyin Pills on the quality of life in the stable phase of COPD (spleen and kidney yang deficiency, phlegm obstructing the lung syndrome);
(4) Evaluate the safety of the clinical use of Tanyin Pills;
(5) Explore the effectiveness of the clinical application of Tanyin Pills in the treatment of stable COPD (spleen and kidney yang deficiency, phlegm obstructing the lung syndrome).
|
药物成份或治疗方案详述:
|
用药方法:
试验药组:西医基础治疗+痰饮丸:一次14丸,一日2次。
安慰剂组:西医基础治疗+痰饮丸模拟剂:一次14丸,一日2次。
基础治疗:进入研究前如使用短效或长效支气管舒张剂(包括β2-受体激动剂、抗胆碱药及茶碱)吸入用糖皮质激素+长效支气管扩张剂联合制剂、粘液溶解剂及镇咳药者在研究期间中可继续使用,但药物种类和用药剂量应维持不变。进入研究前未用任何药的患者根据临床医生判断,至少使用一种支气管扩张剂作为基础治疗。
最长用药疗程:52周。
治疗期:患者至少使用试验药物8周,出现首次AECOPD发作即结束治疗进入随访期,如用药52周后,仍未发生AECOPD,则完成试验。
随访期:出现AECOPD后结束治疗,进入随访,最长随访至52周。
最短用药疗程定义为8周,即用药8周内发生AECOPD患者不计为有效病例。
|
Description for medicine or protocol of treatment in detail:
|
Medication method:
Experimental drug group: Western medicine basic treatment + phlegm drink pills: 14 pills each time, 2 times a day.
Placebo group: basic western medicine treatment + phlegm-yin pill simulation agent: 14 pills each time, 2 times a day.
Basic treatment: Before entering the study, such as the use of short-acting or long-acting bronchodilators (including β2-receptor agonists, anticholinergics and theophylline) inhaled glucocorticoid + long-acting bronchodilator combination preparation, mucolytic agent and antitussive The drug user can continue to use the drug during the study period, but the type of drug and the dosage of the drug should remain unchanged. Patients who did not take any medication before entering the study should use at least one bronchodilator as the basic treatment based on the judgment of the clinician.
The longest medication course: 52 weeks.
Treatment period: The patient has used the test drug for at least 8 weeks, and the first AECOPD episode will end the treatment and enter the follow-up period. If AECOPD has not occurred after 52 weeks of medication, the trial will be completed.
Follow-up period: After the occurrence of AECOPD, the treatment is ended and the follow-up is entered. The longest follow-up is 52 weeks.
The shortest course of medication is defined as 8 weeks, that is, patients with AECOPD within 8 weeks of medication are not counted as effective cases.
|
纳入标准:
|
1. 符合慢性阻塞性肺疾病西医诊断标准;
2. 符合 GOLD中肺功能中重度的门诊患者;
3. 符合急性加重高风险患者;
4. 符合中医脾肾阳虚,痰饮阻肺证辨证标准;
5. 年龄40-80周岁;
6. 同意参加本研究并签署知情同意书。
|
Inclusion criteria
|
1. Meet the diagnostic criteria of western medicine for chronic obstructive pulmonary disease;
2. Outpatients with moderate to severe lung function in compliance with GOLD;
3. In line with patients with high risk of acute exacerbation;
4. Comply with the syndrome differentiation standard of spleen and kidney yang deficiency and phlegm-drinking obstructing lung syndrome;
5. Aged from 40 to 80 years;
6. Agree to participate in this study and sign an informed consent form.
|
排除标准:
|
1. 伴有哮喘、活动性结核病、肺癌、支气管扩张症、肺栓塞、肺心病、肺间质性疾病或其他活动性疾病者;
2. 就诊前1个月内有AECOPD或感染患者;
3. 需要长期氧疗患者(每日吸氧时间≥12h)或正在接受肺康复治疗患者;
4. 既往行肺切除术,或筛选前12个月内接受肺减容手术者;
5. 患有严重的高血压、心力衰竭、心律失常、糖尿病、肿瘤,原发性心、肝、肾、血液系统疾病控制不理想者;
6. 肾脏Scr超过参考值上限1.5倍,或肝功能检查AST、ALT≥2倍参考值上限者;
7. 已知或疑似酒精或药物滥用史者;
8. 妊娠或哺乳期女性或计划在研究期间妊娠者;
9. 对研究药物成分过敏者及说明书中不适宜使用的患者;
10. 近3个月内参加过其他临床试验者;
11. 研究者判定不适合参与本临床试验者。
|
Exclusion criteria:
|
1. Accompanied by asthma, active tuberculosis, lung cancer, bronchiectasis, pulmonary embolism, pulmonary heart disease, pulmonary interstitial disease or other active diseases;
2. Patients with AECOPD or infection within 1 month before the consultation;
3. Patients who need long-term oxygen therapy (daily oxygen inhalation time >=12h) or patients undergoing pulmonary rehabilitation;
4. Pneumonectomy in the past, or lung volume reduction surgery within 12 months before screening;
5. Those suffering from severe hypertension, heart failure, arrhythmia, diabetes, tumors, and unsatisfactory control of primary heart, liver, kidney, and blood system diseases;
6. Kidney Scr exceeds the upper limit of the reference value by 1.5 times, or the liver function test AST, ALT >=2 times the upper limit of the reference value;
7. Those with known or suspected history of alcohol or drug abuse;
8. Pregnant or lactating women or those planning to become pregnant during the study period;
9. Those who are allergic to the ingredients of the study drug and those who are not suitable for use in the instructions;
10. Those who have participated in other clinical trials within the past 3 months;
11. Those who are judged by the investigator to be unsuitable to participate in this clinical trial.
|
研究实施时间:
Study execute time:
|
从From
2020-12-01
至To
2023-11-01
|
征募观察对象时间:
Recruiting time:
|
从From
2021-07-11
至To
2022-09-30
|